Omeros (OMER) – A Snapshot of Recent Activity
Trading Performance
Omeros Corporation, the Seattle‑based biopharmaceutical firm, closed its most recent trading session up 1.22 % during a 24‑hour window that ended at 04:37 AM Central European Time on Thursday, 22 April 2026. At the time of reporting, one share of Omeros could be purchased for approximately USD 16.26 on major exchanges.
The company’s market capitalization stands at USD 1.2 billion, with a free float of 72.2 million shares. In the past 24 hours, roughly USD 12 million worth of Omeros stock exchanged hands. However, since the close of the previous month, the stock has declined by 10.49 %.
Omeros’ 200‑day simple moving average currently sits at USD 13.33, while the high of the past 52 weeks was USD 21.24 on 22 September 2026. The 52‑week low was USD 6.24 on 13 November 2025.
Peer Comparison (24‑Hour Activity)
| Stock | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|
| Del Monte (DMC) | –0.37 % | USD 27.90 | USD 1.4 billion | 41.51 |
| Ivanhoe Electric/US (IE) | –3.76 % | USD 8.49 | USD 1.4 billion | – |
| Nexteer Automotive (1316.HK) | –0.34 % | HKD 4.21 | HKD 11.1 billion | 11.45 |
| Hillman (HLMN) | +0.28 % | USD 7.26 | USD 1.4 billion | 36.43 |
| Eton (ETON) | +1.97 % | USD 49.30 | USD 1.4 billion | 115.71 |
While the majority of peer firms exhibited modest declines, Eton and Hillman displayed gains, underscoring the varied market sentiment across the sector.
Business Focus
Omeros Corporation is headquartered in Seattle, Washington, and concentrates on developing a broad pipeline of product candidates across several therapeutic areas, including orthopedics, rheumatology, urology, cardiovascular medicine, general surgery, and pain management. Its strategic emphasis on diversified indications positions it as a notable player in the biopharmaceutical landscape.
Outlook
Investors should note Omeros’ recent volatility relative to its peers, as well as its substantial decline since the end of March. The company’s performance will likely be influenced by upcoming clinical data releases and regulatory milestones. As with any biopharmaceutical investment, careful consideration of both the scientific pipeline and market dynamics is essential for informed decision‑making.
